news

CUPERTINO, Calif., April 28 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC Annual Biotechnology and Specialty Pharmaceuticals Conference. The conference is being held at The Millennium Hotel in New York City. James E. Brown, DVM, Chief Executive Officer, will be presenting at the conference on Wednesday, April 30, […]

CUPERTINO, Calif., April 15 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) first quarter 2003 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, April 28, 2003 at 4:30 p.m. EST with Jim Brown, President and Chief Executive Officer, Tom

CUPERTINO, Calif., Jan. 28 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2002. DURECT’s net loss for the three months ended December 31, 2002 was $8.5 million or 17 cents per share, compared to $10.1 million or 21 cents per share for the same

CUPERTINO, Calif., Jan. 15 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) fourth quarter and year end 2002 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Tuesday, January 28, 2003 at 4:30 p.m. EST with Jim Brown, President and Chief

SOUTH SAN FRANCISCO, Calif. and CUPERTINO, Calif., Jan. 14 /PRNewswire- FirstCall/ — Pain Therapeutics, Inc. (Nasdaq: PTIE) and DURECT Corporation (Nasdaq: DRRX) today announced they have signed an exclusive licensing agreement to formulate certain long-acting opioid drugs. Opioid drugs, sometimes called ‘narcotic painkillers,’ are widely used to treat moderate to severe pain. In the U.S.,

CUPERTINO, Calif., Jan. 2 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the JPMorgan H&Q 21st Annual Healthcare Conference. The conference is taking place January 6-9th at The Westin St. Francis Hotel in San Francisco. Dr. James E. Brown, President and Chief Executive Officer will be presenting at the conference

CUPERTINO, Calif., Dec. 27 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that the company has appointed David R. Hoffmann to its Board of Directors to replace Matthew V. McPherron who is stepping down as a member of the Board of Directors. (Photo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) “Matt McPherron has served DURECT very well during the past

CUPERTINO, Calif., Nov. 22 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) today announced that it is reducing operating expenses in accordance with the Company’s overall corporate objectives for the fiscal year 2003. DURECT’s long-term strategy and business plan remain on track. The Company is reducing personnel levels to focus specifically on the CHRONOGESIC(TM) product and development

ZUG, Switzerland and CUPERTINO, Calif., Nov. 19 /PRNewswire-FirstCall/ — BioPartners, a global biopharmaceuticals company and one of the leaders in the emerging field of competitively priced multi-source biopharmaceuticals, has signed an exclusive agreement with DURECT Corporation (Nasdaq: DRRX), a U.S. based pioneering pharmaceutical systems company, for the development of a sustained release formulation of recombinant

CUPERTINO, Calif., Nov. 14 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) and Thorn BioScience LLC announced today that the two companies have expanded their agreement for the development and commercialization of veterinary products for reproductive indications using DURECT’s SABER(TM) Delivery System. The SABER technology has the potential to successfully deliver therapeutic levels of a wide spectrum